<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195663</url>
  </required_header>
  <id_info>
    <org_study_id>DE013</org_study_id>
    <nct_id>NCT00195663</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis</brief_title>
  <acronym>PREMIER</acronym>
  <official_title>A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFα Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatoid Arthritis (PREMIER).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and efficacy of adalimumab in combination
      with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the
      long-term safety and maintenance of efficacy after treatment with adalimumab for up to 10
      years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study had an initial 2-year double-blind treatment period followed by an 8-year
      open-label extension period, for a total of up to 10 years study duration. The study was
      designed to assess the potential of adalimumab + methotrexate to improve signs and symptoms
      of disease and to inhibit radiographic progression in patients with recent onset (disease
      duration less than 3 years) rheumatoid arthritis not previously treated with methotrexate.
      Adalimumab is a human anti-tumor necrosis factor (TNF) monoclonal antibody.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52</measure>
    <time_frame>Baseline and 52 Weeks</time_frame>
    <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
Acute phase reactant value (C-Reactive Protein).
Participants who withdrew early were considered non-responders.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 52 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104</measure>
    <time_frame>Baseline and Week 104</time_frame>
    <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104</measure>
    <time_frame>Baseline and Week 104</time_frame>
    <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 104 were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score &lt; 2.6 at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health were included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Clinical Response After 104 Weeks of Treatment</measure>
    <time_frame>Any 6 continuous months from Baseline to Week 104</time_frame>
    <description>Major clinical response was defined as an American College of Rheumatology 70% (ACR70) response for any six continuous months, over 104 weeks of treatment. A participant was a responder if the following criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76</measure>
    <time_frame>Baseline and Weeks 26 and 76</time_frame>
    <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase</measure>
    <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
    <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase</measure>
    <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
    <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase</measure>
    <time_frame>Baseline and Weeks 12, 26, 76, and 104</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase</measure>
    <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase</measure>
    <time_frame>Baseline and Weeks 26, 52, and 104</time_frame>
    <description>The HUI 2/3 is an assessment of various aspects of participants' health and ability to perform various tasks on a day-to-day basis, including reading, seeing, hearing, speaking, general outlook on life, pain/discomfort, ability to walk, use of hands, memory, ability to think/solve, and ability to perform basic activities such as eating, bathing, and dressing. The HUI 2/3 is a combined 15-item questionnaire based on a recall period of the previous 4 weeks. HUI-2 and HUI-3 scores are calculated independently. The HUI-2 score includes 6 attributes: Sensation, Mobility, Emotion, Cognition, Self-Care, and Pain. The HUI-3 score is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition, and Pain.
The range of each score is from 0 (dead) to 1 (perfect health). An increase from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase</measure>
    <time_frame>Baseline and Weeks 26 and 104</time_frame>
    <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component and items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase</measure>
    <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
    <description>ACR-N is a composite, continuous variable which measures the percentage of improvement from Baseline in individual participants based on the 7 core set variables of the ACR. ACR-N is defined as the smallest percent change from Baseline of 3 measures: tender joint counts (TJC), swollen joint counts (SJC), and the median percent improvement in the 5 remaining measures (Patient's Assessment of Pain, Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Health Assessment Questionnaire - Disability Index [HAQ-DI], and C-Reactive Protein). A positive ACR-N value indicates improvement; a negative ACR-N value indicates worsening; ACR-N of 0 indicates no change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase</measure>
    <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
    <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period</measure>
    <time_frame>Baseline and Weeks 52 and 104</time_frame>
    <description>Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with &gt;80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion)to 230 (worst). A large increase in erosion score is indicative of worsening, whereas a small change or no change is indicative of inhibition of joint erosion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period</measure>
    <time_frame>Baseline and Weeks 52 and 104</time_frame>
    <description>Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joint space narrowing (JSN) scores were recorded for each hand/wrist (16 joints) and each forefoot (5 joints) on a 5-point scale (0 = no narrowing; 1 = up to 25% narrowing; 2 = 26-65% narrowing; 3 = 66-99% narrowing; and 4 = complete narrowing). Scores were summed to calculate the total score ranging from 0 (no narrowing) to 168 (maximum narrowing). A large increase in joint narrowing score is indicative of worsening, whereas a small change or no change is indicative of inhibition of JSN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase</measure>
    <time_frame>Baseline and Weeks 52 and 104</time_frame>
    <description>The number of participants with no worsening in the modified Total Sharp Score (mTSS) and in erosion and joint space narrowing (JSN) scores, where no worsening is defined as a change from Baseline of ≤ 0 in mTSS, erosion score and JSN score, at Weeks 52 and 104.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104</measure>
    <time_frame>Baseline and Weeks 52 and 104</time_frame>
    <description>The number of participants with no erosions at Baseline and no erosions at Weeks 52 and 104, where no erosions and no new erosions are defined as an erosion score = 0.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with &gt;80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion) to 230 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104</measure>
    <time_frame>Baseline and Weeks 52 and 104</time_frame>
    <description>Number of participants with non-involved joints at Baseline and no newly involved joints at Weeks 52 and 104, where involved joints or no newly involved joints are defined as modified Total Sharp Score (mTSS) = 0.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure</measure>
    <time_frame>Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.</time_frame>
    <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For participants randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure</measure>
    <time_frame>Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.</time_frame>
    <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure</measure>
    <time_frame>Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.</time_frame>
    <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure</measure>
    <time_frame>Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure</measure>
    <time_frame>Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.</time_frame>
    <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With DAS28 &lt; 2.6 and &lt; 3.2 Over 10 Years by Adalimumab Exposure</measure>
    <time_frame>After 1, 2, 5, and 10 years of adalimumab exposure</time_frame>
    <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years</measure>
    <time_frame>Baseline (prior to first study drug treatment) and Years 2 and 10</time_frame>
    <description>The modified TSS (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With No Radiographic Progression Over 10 Years</measure>
    <time_frame>Baseline (prior to first study drug treatment) and Years 2 and 10.</time_frame>
    <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. The number of participants with change from Baseline ≤ 0.5 and ≤ 0 is reported as a measure of no disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Score of ACR50 Plus No Change in Modified Total Sharp Score</measure>
    <time_frame>Year 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure</measure>
    <time_frame>From the first dose of adalimumab (at Week 1 or Week 106 for patients initially randomized to methotrexate in the DB phase) to Year 10</time_frame>
    <description>A major clinical response was defined as maintenance of an ACR70 response for at least a 6-month continuous period at any time during the study following the first dose of adalimumab. A participant was a responder if the following criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure</measure>
    <time_frame>Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A decrease in the HAQ-DI score represents an improvement in physical function; a clinically significant improvement is defined as a decrease of least 0.22 from Baseline in the HAQ-DI score. The number of participants with improvement in HAQ-DI of at least 0.22 and 0.5 units from Baseline is reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">799</enrollment>
  <condition>Early Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab + methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_label>Adalimumab + methotrexate</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Adalimumab + methotrexate</arm_group_label>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab placebo</intervention_name>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate placebo</intervention_name>
    <arm_group_label>Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was age 18 or older and in good health (Investigator discretion) with a recent
             stable medical history.

          -  Diagnosis of rheumatoid arthritis (RA) as defined by the 1987-revised American College
             of Rheumatology (ACR) criteria, with a disease duration less than 3 years, at least 8
             swollen joints out of the 66 joints assessed, at least 10 tender joints out of the 68
             joints assessed, at least 1 joint erosion or rheumatoid factor (RF) positivity,
             erythrocyte sedimentation rate (ESR) &gt;= 28 mm/1h or C-reactive protein (CRP) &gt;= 1.5
             mg/dl

        Exclusion Criteria:

          -  Chronic arthritis diagnosed before the age of 16

          -  Preceding treatment with MTX, cyclophosphamide, cyclosporin, azathioprine or more than
             2 other disease-modifying anti-rheumatic drugs (DMARDs)

          -  Subject previously received anti-tumor necrosis factor (TNF) therapy

          -  Permanently wheelchair-bound or bedridden patients

          -  Subject considered by the investigator, for any reason, to be an unsuitable candidate
             for the study

          -  Female subject who is pregnant or breast-feeding or considering becoming pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Carlson</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 322</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95957</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 429</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 2491</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 2500</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 762</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 328</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 327</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 325</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 302</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 319</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95960</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 326</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 2533</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605-0000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 336</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 318</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 488</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 314</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 761</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 757</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 361</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 316</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4649</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 96122</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 306</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 313</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 2437</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 2532</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 758</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 321</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 305</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 310</name>
      <address>
        <city>Brisbane</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 755</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 337</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 331</name>
      <address>
        <city>Darlinghurst, Sydney</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 745</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 738</name>
      <address>
        <city>Maroochydore</city>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 335</name>
      <address>
        <city>New Lambton</city>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 737</name>
      <address>
        <city>Shenton Park</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 307</name>
      <address>
        <city>South Hobart</city>
        <zip>7004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 427</name>
      <address>
        <city>West Heidelberg</city>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 739</name>
      <address>
        <city>Woodville</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 344</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 753</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 308</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 752</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 748</name>
      <address>
        <city>Diepenbeek</city>
        <zip>3590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6136</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 98256</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 333</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 98199</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3H 5Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4646</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2S2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 303</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 330</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4634</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 311</name>
      <address>
        <city>Montreal</city>
        <zip>H3Z 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 309</name>
      <address>
        <city>Newmarket</city>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 304</name>
      <address>
        <city>Pointe-Claire</city>
        <zip>H9J 3W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4633</name>
      <address>
        <city>Richmond</city>
        <zip>V7C 5L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 763</name>
      <address>
        <city>St. John's</city>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4635</name>
      <address>
        <city>Toronto</city>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 490</name>
      <address>
        <city>Toronto</city>
        <zip>M5L 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 760</name>
      <address>
        <city>Victoria</city>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4632</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3N OK6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 754</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 332</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 734</name>
      <address>
        <city>Prague 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95878</name>
      <address>
        <city>Grasten</city>
        <zip>6300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6135</name>
      <address>
        <city>Heinola</city>
        <zip>FI-18120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6134</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 428</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 348</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4650</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3415</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 733</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 346</name>
      <address>
        <city>Strasbourg, Cedex 1</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3417</name>
      <address>
        <city>Berlin-Buch</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4631</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 759</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4630</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 347</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 742</name>
      <address>
        <city>Goerlitz</city>
        <zip>02826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 746</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 98125</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 339</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 744</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 338</name>
      <address>
        <city>Vogelsang-Gommern</city>
        <zip>39245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 740</name>
      <address>
        <city>Cork</city>
        <zip>WDQ-23-KM9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 751</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95719</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 323</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 345</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 756</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 343</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6133</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 317</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 315</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95800</name>
      <address>
        <city>Osla</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95875</name>
      <address>
        <city>Osla</city>
        <zip>0370</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3426</name>
      <address>
        <city>Piestany</city>
        <zip>92112</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 96121</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 735</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 1525</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 1528</name>
      <address>
        <city>Barcelona</city>
        <zip>08915</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 750</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 1526</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 741</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 390</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 749</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 728</name>
      <address>
        <city>Stockholm</city>
        <zip>113 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 2565</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4638</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 96126</name>
      <address>
        <city>Umea</city>
        <zip>901 84</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 747</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 96120</name>
      <address>
        <city>Vasteras</city>
        <zip>S-721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 736</name>
      <address>
        <city>Vasteras</city>
        <zip>S-721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 334</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 96116</name>
      <address>
        <city>Bangor</city>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95877</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 98258</name>
      <address>
        <city>Hereford</city>
        <zip>HR1 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95795</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 95958</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 98255</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>December 8, 2009</results_first_submitted>
  <results_first_submitted_qc>February 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2010</results_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at 94 sites in 15 countries between January 2001 and April 2004.</recruitment_details>
      <pre_assignment_details>Patients who had been receiving a previous disease-modifying anti-rheumatic drug (DMARD) participated in a 4-week washout period during which the DMARD was withdrawn. Otherwise, there was a one-week washout period after the Screening visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methotrexate</title>
          <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
        </group>
        <group group_id="P2">
          <title>Adalimumab</title>
          <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.</description>
        </group>
        <group group_id="P3">
          <title>Adalimumab + Methotrexate</title>
          <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>2-year Double-blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="274"/>
                <participants group_id="P3" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Planned selection criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recovery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="159"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="97"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recovery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methotrexate</title>
          <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
        </group>
        <group group_id="B2">
          <title>Adalimumab</title>
          <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.</description>
        </group>
        <group group_id="B3">
          <title>Adalimumab + Methotrexate</title>
          <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="257"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="268"/>
            <count group_id="B4" value="799"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="13.1"/>
                    <measurement group_id="B2" value="52.1" spread="13.5"/>
                    <measurement group_id="B3" value="51.9" spread="14.0"/>
                    <measurement group_id="B4" value="52.0" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="193"/>
                    <measurement group_id="B4" value="595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52</title>
        <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient’s self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
Acute phase reactant value (C-Reactive Protein).
Participants who withdrew early were considered non-responders.</description>
        <time_frame>Baseline and 52 Weeks</time_frame>
        <population>The Full Analysis Set consisted of all patients who were randomized and who received at least one dose of double-blinded study medication. Participants with insufficient data to calculate ACR50 at Week 52 or who withdrew early were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52</title>
          <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient’s self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
Acute phase reactant value (C-Reactive Protein).
Participants who withdrew early were considered non-responders.</description>
          <population>The Full Analysis Set consisted of all patients who were randomized and who received at least one dose of double-blinded study medication. Participants with insufficient data to calculate ACR50 at Week 52 or who withdrew early were considered non-responders.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study was powered to demonstrate the superiority of adalimumab + MTX combination therapy vs. MTX monotherapy in the proportion of subjects who achieved an ACR50 response at 52 weeks. Power calculations were based on 250 subjects in each group using a chi-squared test with a continuity correction and an alpha = 0.05 significance level. With 250 subjects in each group, a difference of 0.13 in response rates could be detected with 80% power.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical tests were performed in a hierarchical manner. If there was a statistically significant difference in favor of adalimumab + MTX combination treatment, the second primary analysis of the modified Total Sharp Score was to be performed.</p_value_desc>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</title>
        <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 52 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Full analysis set. For participants with missing data, mTSS was imputed by linear extrapolation.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</title>
          <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 52 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>Full analysis set. For participants with missing data, mTSS was imputed by linear extrapolation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="12.7" lower_limit="-58.0" upper_limit="78.5"/>
                    <measurement group_id="O2" value="3.0" spread="11.2"/>
                    <measurement group_id="O3" value="1.3" spread="6.5" lower_limit="-68.0" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical tests were performed in a hierarchical manner. If there was a statistically significant difference in favor of adalimumab + MTX combination treatment on the ACR50 response, the second primary analysis of modified TSS would be performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
          <population>Full analysis set with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.6"/>
                    <measurement group_id="O2" value="-0.8" spread="0.7"/>
                    <measurement group_id="O3" value="-1.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104</title>
        <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient’s self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
        <time_frame>Baseline and Week 104</time_frame>
        <population>Full analysis set. Participants with insufficient data to calculate ACR50 at Week 104 or who withdrew early were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104</title>
          <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient’s self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
          <population>Full analysis set. Participants with insufficient data to calculate ACR50 at Week 104 or who withdrew early were considered non-responders.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104</title>
        <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 104 were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Baseline and Week 104</time_frame>
        <population>Full analysis set. For participants with missing data, mTSS was imputed by linear extrapolation.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104</title>
          <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 104 were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>Full analysis set. For participants with missing data, mTSS was imputed by linear extrapolation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="21.7"/>
                    <measurement group_id="O2" value="5.5" spread="15.8"/>
                    <measurement group_id="O3" value="1.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score &lt; 2.6 at Week 52</title>
        <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health were included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set. Participants with insufficient data to calculate DAS28 at Week 52 or who withdrew early were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score &lt; 2.6 at Week 52</title>
          <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health were included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>Full analysis set. Participants with insufficient data to calculate DAS28 at Week 52 or who withdrew early were considered non-responders.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52</title>
        <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52</title>
          <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
          <population>Full analysis set with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="9.6"/>
                    <measurement group_id="O2" value="12.6" spread="10.0"/>
                    <measurement group_id="O3" value="16.7" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Clinical Response After 104 Weeks of Treatment</title>
        <description>Major clinical response was defined as an American College of Rheumatology 70% (ACR70) response for any six continuous months, over 104 weeks of treatment. A participant was a responder if the following criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient’s self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were non-responders.</description>
        <time_frame>Any 6 continuous months from Baseline to Week 104</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Weekly</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Clinical Response After 104 Weeks of Treatment</title>
          <description>Major clinical response was defined as an American College of Rheumatology 70% (ACR70) response for any six continuous months, over 104 weeks of treatment. A participant was a responder if the following criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient’s self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were non-responders.</description>
          <population>Full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52</title>
        <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52</title>
          <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
          <population>Full analysis set with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="11.0"/>
                    <measurement group_id="O2" value="7.1" spread="12.3"/>
                    <measurement group_id="O3" value="7.2" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5402</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76</title>
        <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
        <time_frame>Baseline and Weeks 26 and 76</time_frame>
        <population>Full analysis set. Participants with insufficient data to calculate ACR50 or who withdrew early were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76</title>
          <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
          <population>Full analysis set. Participants with insufficient data to calculate ACR50 or who withdrew early were considered non-responders.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase</title>
        <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
        <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
        <population>Full analysis set. Participants with insufficient data to calculate ACR20 or who withdrew early were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase</title>
          <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
          <population>Full analysis set. Participants with insufficient data to calculate ACR20 or who withdrew early were considered non-responders.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="137"/>
                    <measurement group_id="O3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase</title>
        <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
        <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
        <population>Full analysis set. Participants with insufficient data to calculate ACR70 or who withdrew early were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase</title>
          <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Participants withdrawing early were considered non-responders.</description>
          <population>Full analysis set. Participants with insufficient data to calculate ACR70 or who withdrew early were considered non-responders.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
        <time_frame>Baseline and Weeks 12, 26, 76, and 104</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
          <population>Full analysis set with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 [N=236, 246, 252]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.6"/>
                    <measurement group_id="O2" value="-0.6" spread="0.6"/>
                    <measurement group_id="O3" value="-0.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 [N=217, 222, 240]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.6"/>
                    <measurement group_id="O2" value="-0.8" spread="0.7"/>
                    <measurement group_id="O3" value="-0.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76 [N= 176, 175, 207]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.6"/>
                    <measurement group_id="O2" value="-0.9" spread="0.7"/>
                    <measurement group_id="O3" value="-1.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [166, 162, 201]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.6"/>
                    <measurement group_id="O2" value="-0.9" spread="0.6"/>
                    <measurement group_id="O3" value="-1.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.</description>
        <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
        <population>Full analysis set. Missing values were considered to be &lt; 0.3.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.</description>
          <population>Full analysis set. Missing values were considered to be &lt; 0.3.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase</title>
        <description>The HUI 2/3 is an assessment of various aspects of participants’ health and ability to perform various tasks on a day-to-day basis, including reading, seeing, hearing, speaking, general outlook on life, pain/discomfort, ability to walk, use of hands, memory, ability to think/solve, and ability to perform basic activities such as eating, bathing, and dressing. The HUI 2/3 is a combined 15-item questionnaire based on a recall period of the previous 4 weeks. HUI-2 and HUI-3 scores are calculated independently. The HUI-2 score includes 6 attributes: Sensation, Mobility, Emotion, Cognition, Self-Care, and Pain. The HUI-3 score is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition, and Pain.
The range of each score is from 0 (dead) to 1 (perfect health). An increase from Baseline indicates improvement.</description>
        <time_frame>Baseline and Weeks 26, 52, and 104</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase</title>
          <description>The HUI 2/3 is an assessment of various aspects of participants’ health and ability to perform various tasks on a day-to-day basis, including reading, seeing, hearing, speaking, general outlook on life, pain/discomfort, ability to walk, use of hands, memory, ability to think/solve, and ability to perform basic activities such as eating, bathing, and dressing. The HUI 2/3 is a combined 15-item questionnaire based on a recall period of the previous 4 weeks. HUI-2 and HUI-3 scores are calculated independently. The HUI-2 score includes 6 attributes: Sensation, Mobility, Emotion, Cognition, Self-Care, and Pain. The HUI-3 score is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition, and Pain.
The range of each score is from 0 (dead) to 1 (perfect health). An increase from Baseline indicates improvement.</description>
          <population>Full analysis set with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HUI-2: Week 26 [N=192, 187, 205]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                    <measurement group_id="O3" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUI-2: Week 52 [N=179, 162, 189]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                    <measurement group_id="O3" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUI-2: Week 104 [N=152, 136, 174]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                    <measurement group_id="O3" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUI-3: Week 26 [N=192, 189, 205]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.3"/>
                    <measurement group_id="O3" value="0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUI-3: Week 52 [N=177, 164, 190]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.3"/>
                    <measurement group_id="O3" value="0.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUI-3: Week 104 [N=154, 138, 177]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.3"/>
                    <measurement group_id="O3" value="0.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase</title>
        <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component and items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
        <time_frame>Baseline and Weeks 26 and 104</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase</title>
          <description>The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component and items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.</description>
          <population>Full analysis set with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component: Week 26 [N=199, 204, 221]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="10.0"/>
                    <measurement group_id="O2" value="10.8" spread="10.2"/>
                    <measurement group_id="O3" value="14.7" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component: Week 104 [160, 157, 189]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="10.3"/>
                    <measurement group_id="O2" value="13.4" spread="9.7"/>
                    <measurement group_id="O3" value="16.8" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component: Week 26 [N=199, 204, 221]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="11.6"/>
                    <measurement group_id="O2" value="5.2" spread="13.5"/>
                    <measurement group_id="O3" value="6.3" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component: Week 104 [N=160, 157, 189]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="10.9"/>
                    <measurement group_id="O2" value="6.6" spread="13.5"/>
                    <measurement group_id="O3" value="6.8" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase</title>
        <description>ACR-N is a composite, continuous variable which measures the percentage of improvement from Baseline in individual participants based on the 7 core set variables of the ACR. ACR-N is defined as the smallest percent change from Baseline of 3 measures: tender joint counts (TJC), swollen joint counts (SJC), and the median percent improvement in the 5 remaining measures (Patient's Assessment of Pain, Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Health Assessment Questionnaire - Disability Index [HAQ-DI], and C-Reactive Protein). A positive ACR-N value indicates improvement; a negative ACR-N value indicates worsening; ACR-N of 0 indicates no change.</description>
        <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase</title>
          <description>ACR-N is a composite, continuous variable which measures the percentage of improvement from Baseline in individual participants based on the 7 core set variables of the ACR. ACR-N is defined as the smallest percent change from Baseline of 3 measures: tender joint counts (TJC), swollen joint counts (SJC), and the median percent improvement in the 5 remaining measures (Patient's Assessment of Pain, Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Health Assessment Questionnaire - Disability Index [HAQ-DI], and C-Reactive Protein). A positive ACR-N value indicates improvement; a negative ACR-N value indicates worsening; ACR-N of 0 indicates no change.</description>
          <population>Full analysis set with available data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 [N=218, 224, 244]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="42.2"/>
                    <measurement group_id="O2" value="39.1" spread="43.3"/>
                    <measurement group_id="O3" value="57.0" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=194, 193, 220]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="48.2"/>
                    <measurement group_id="O2" value="44.4" spread="52.2"/>
                    <measurement group_id="O3" value="66.3" spread="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76 [N=181, 179, 211]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="38.1"/>
                    <measurement group_id="O2" value="51.5" spread="56.8"/>
                    <measurement group_id="O3" value="68.8" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=168, 167, 203]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="37.1"/>
                    <measurement group_id="O2" value="54.0" spread="42.7"/>
                    <measurement group_id="O3" value="71.4" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase</title>
        <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
        <time_frame>Baseline and Weeks 26, 52, 76, and 104</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase</title>
          <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
          <population>Full analysis set with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 [N=209, 218, 229]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="1.3"/>
                    <measurement group_id="O2" value="-2.4" spread="1.4"/>
                    <measurement group_id="O3" value="-3.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=184, 185, 206]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.4"/>
                    <measurement group_id="O2" value="-2.8" spread="1.5"/>
                    <measurement group_id="O3" value="-3.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76 [N=173, 173, 197]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="1.2"/>
                    <measurement group_id="O2" value="-3.0" spread="1.5"/>
                    <measurement group_id="O3" value="-3.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=161, 158, 191]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="1.4"/>
                    <measurement group_id="O2" value="-3.2" spread="1.4"/>
                    <measurement group_id="O3" value="-3.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period</title>
        <description>Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21–40% joint involvement; 3 = 3 separate quadrants with erosion or 41–60% joint involvement; 4 = all 4 quadrants with erosion or 61–80% joint involvement; and 5 = extensive destruction with &gt;80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion)to 230 (worst). A large increase in erosion score is indicative of worsening, whereas a small change or no change is indicative of inhibition of joint erosion.</description>
        <time_frame>Baseline and Weeks 52 and 104</time_frame>
        <population>Full analysis set. Missing values were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period</title>
          <description>Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21–40% joint involvement; 3 = 3 separate quadrants with erosion or 41–60% joint involvement; 4 = all 4 quadrants with erosion or 61–80% joint involvement; and 5 = extensive destruction with &gt;80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion)to 230 (worst). A large increase in erosion score is indicative of worsening, whereas a small change or no change is indicative of inhibition of joint erosion.</description>
          <population>Full analysis set. Missing values were imputed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="8.4"/>
                    <measurement group_id="O2" value="1.7" spread="5.7"/>
                    <measurement group_id="O3" value="0.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="14.3"/>
                    <measurement group_id="O2" value="3.0" spread="8.3"/>
                    <measurement group_id="O3" value="1.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period</title>
        <description>Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joint space narrowing (JSN) scores were recorded for each hand/wrist (16 joints) and each forefoot (5 joints) on a 5-point scale (0 = no narrowing; 1 = up to 25% narrowing; 2 = 26–65% narrowing; 3 = 66–99% narrowing; and 4 = complete narrowing). Scores were summed to calculate the total score ranging from 0 (no narrowing) to 168 (maximum narrowing). A large increase in joint narrowing score is indicative of worsening, whereas a small change or no change is indicative of inhibition of JSN.</description>
        <time_frame>Baseline and Weeks 52 and 104</time_frame>
        <population>Full analysis set. Missing values were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period</title>
          <description>Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joint space narrowing (JSN) scores were recorded for each hand/wrist (16 joints) and each forefoot (5 joints) on a 5-point scale (0 = no narrowing; 1 = up to 25% narrowing; 2 = 26–65% narrowing; 3 = 66–99% narrowing; and 4 = complete narrowing). Scores were summed to calculate the total score ranging from 0 (no narrowing) to 168 (maximum narrowing). A large increase in joint narrowing score is indicative of worsening, whereas a small change or no change is indicative of inhibition of JSN.</description>
          <population>Full analysis set. Missing values were imputed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="6.3"/>
                    <measurement group_id="O2" value="1.3" spread="6.6"/>
                    <measurement group_id="O3" value="0.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="10.9"/>
                    <measurement group_id="O2" value="2.6" spread="9.5"/>
                    <measurement group_id="O3" value="0.9" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase</title>
        <description>The number of participants with no worsening in the modified Total Sharp Score (mTSS) and in erosion and joint space narrowing (JSN) scores, where no worsening is defined as a change from Baseline of ≤ 0 in mTSS, erosion score and JSN score, at Weeks 52 and 104.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Baseline and Weeks 52 and 104</time_frame>
        <population>Full analysis set. Participants with missing data or who withdrew early were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase</title>
          <description>The number of participants with no worsening in the modified Total Sharp Score (mTSS) and in erosion and joint space narrowing (JSN) scores, where no worsening is defined as a change from Baseline of ≤ 0 in mTSS, erosion score and JSN score, at Weeks 52 and 104.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>Full analysis set. Participants with missing data or who withdrew early were considered non-responders.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Modified Total Sharp Score: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified Total Sharp Score: Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion Scoe: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion Score: Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Space Narrowing Score: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Space Narrowing Score: Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104</title>
        <description>The number of participants with no erosions at Baseline and no erosions at Weeks 52 and 104, where no erosions and no new erosions are defined as an erosion score = 0.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21–40% joint involvement; 3 = 3 separate quadrants with erosion or 41–60% joint involvement; 4 = all 4 quadrants with erosion or 61–80% joint involvement; and 5 = extensive destruction with &gt;80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion) to 230 (worst).</description>
        <time_frame>Baseline and Weeks 52 and 104</time_frame>
        <population>Full analysis set participants with no erosions at Baseline and non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104</title>
          <description>The number of participants with no erosions at Baseline and no erosions at Weeks 52 and 104, where no erosions and no new erosions are defined as an erosion score = 0.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21–40% joint involvement; 3 = 3 separate quadrants with erosion or 41–60% joint involvement; 4 = all 4 quadrants with erosion or 61–80% joint involvement; and 5 = extensive destruction with &gt;80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion) to 230 (worst).</description>
          <population>Full analysis set participants with no erosions at Baseline and non-missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104</title>
        <description>Number of participants with non-involved joints at Baseline and no newly involved joints at Weeks 52 and 104, where involved joints or no newly involved joints are defined as modified Total Sharp Score (mTSS) = 0.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]).</description>
        <time_frame>Baseline and Weeks 52 and 104</time_frame>
        <population>Full analysis set participants with non-involved joints at Baseline and non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104</title>
          <description>Number of participants with non-involved joints at Baseline and no newly involved joints at Weeks 52 and 104, where involved joints or no newly involved joints are defined as modified Total Sharp Score (mTSS) = 0.
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]).</description>
          <population>Full analysis set participants with non-involved joints at Baseline and non-missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure</title>
        <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For participants randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
        <time_frame>Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.</time_frame>
        <population>Intent-to-treat (ITT) Analysis Set (all patients who received at least 1 dose of adalimumab during the study, including patients who received their first dose during the DB phase and those who received MTX during the DB phase and adalimumab in the OL phase) with available ACR data. &quot;N&quot; indicates patients with non-missing data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Adalimumab</title>
            <description>Participants received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase. During the 8-year open-label phase all participants received adalimumab 40 mg every other week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure</title>
          <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For participants randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
          <population>Intent-to-treat (ITT) Analysis Set (all patients who received at least 1 dose of adalimumab during the study, including patients who received their first dose during the DB phase and those who received MTX during the DB phase and adalimumab in the OL phase) with available ACR data. &quot;N&quot; indicates patients with non-missing data at each time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 [N=410]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 [N=385]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 [N=325]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10 [N=170]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure</title>
        <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
        <time_frame>Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.</time_frame>
        <population>ITT Analysis Set with available ACR data. &quot;N&quot; indicates patients with non-missing data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Adalimumab</title>
            <description>Participants received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase. During the 8-year open-label phase all participants received adalimumab 40 mg every other week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure</title>
          <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
          <population>ITT Analysis Set with available ACR data. &quot;N&quot; indicates patients with non-missing data at each time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 [N=410]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 [N=385]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 [N=325]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10 [N=170]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure</title>
        <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
        <time_frame>Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.</time_frame>
        <population>ITT Analysis Set with available data. &quot;N&quot; indicates patients with non-missing data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Adalimumab</title>
            <description>Participants received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase. During the 8-year open-label phase all participants received adalimumab 40 mg every other week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure</title>
          <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).
Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.</description>
          <population>ITT Analysis Set with available data. &quot;N&quot; indicates patients with non-missing data at each time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 [N=410]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 [N=385]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 [N=325]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10 [N=170]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
        <time_frame>Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.</time_frame>
        <population>ITT Analysis Set, with available data. &quot;N&quot; indicates patients with non-missing data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Adalimumab</title>
            <description>Participants received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase. During the 8-year open-label phase all participants received adalimumab 40 mg every other week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.</description>
          <population>ITT Analysis Set, with available data. &quot;N&quot; indicates patients with non-missing data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 [N=407]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 [N=390]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 [N=344]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10 [N=170]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure</title>
        <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
        <time_frame>Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.</time_frame>
        <population>ITT Analysis Set, with available data. &quot;N&quot; indicates patients with non-missing data at Baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Adalimumab</title>
            <description>Participants received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase. During the 8-year open-label phase all participants received adalimumab 40 mg every other week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure</title>
          <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
          <population>ITT Analysis Set, with available data. &quot;N&quot; indicates patients with non-missing data at Baseline and the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 [N=403]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 [N=386]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 [N=330]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10 [N=158]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With DAS28 &lt; 2.6 and &lt; 3.2 Over 10 Years by Adalimumab Exposure</title>
        <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
        <time_frame>After 1, 2, 5, and 10 years of adalimumab exposure</time_frame>
        <population>ITT Analysis Set, with available data. The Number of Participants Analyzed indicates patients with non-missing DAS28 scores at any post-baseline time point; &quot;N&quot; indicates patients with non-missing data at each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab: DAS28 &lt; 2.6</title>
            <description>Participants with a DAS28 score less than 2.6, who received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase and adalimumab 40 mg every other week during the 8-year open-label phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab: DAS28 &lt; 3.2</title>
            <description>Participants with a DAS28 score less than 3.2, who received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase and adalimumab 40 mg every other week during the 8-year open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With DAS28 &lt; 2.6 and &lt; 3.2 Over 10 Years by Adalimumab Exposure</title>
          <description>The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:
28 tender joint counts,
28 swollen joint counts,
C-reactive protein, and
Patient's global assessment of disease activity.
Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
          <population>ITT Analysis Set, with available data. The Number of Participants Analyzed indicates patients with non-missing DAS28 scores at any post-baseline time point; &quot;N&quot; indicates patients with non-missing data at each specified time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="694"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 [N=405]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 [N=389]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 [N=333]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10 [N=159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years</title>
        <description>The modified TSS (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Baseline (prior to first study drug treatment) and Years 2 and 10</time_frame>
        <population>ITT Analysis Set, with available data. &quot;N&quot; indicates patients with non-missing radiographic data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years</title>
          <description>The modified TSS (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>ITT Analysis Set, with available data. &quot;N&quot; indicates patients with non-missing radiographic data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 2 [N=83, 92, 89]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="12.44"/>
                    <measurement group_id="O2" value="5.1" spread="9.63"/>
                    <measurement group_id="O3" value="0.3" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10 [N= 83, 93, 90]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="20.01"/>
                    <measurement group_id="O2" value="9.2" spread="15.21"/>
                    <measurement group_id="O3" value="3.9" spread="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With No Radiographic Progression Over 10 Years</title>
        <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. The number of participants with change from Baseline ≤ 0.5 and ≤ 0 is reported as a measure of no disease progression.</description>
        <time_frame>Baseline (prior to first study drug treatment) and Years 2 and 10.</time_frame>
        <population>ITT Analysis Set, with available data. &quot;N&quot; indicates patients with non-missing radiographic data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No Radiographic Progression Over 10 Years</title>
          <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. The number of participants with change from Baseline ≤ 0.5 and ≤ 0 is reported as a measure of no disease progression.</description>
          <population>ITT Analysis Set, with available data. &quot;N&quot; indicates patients with non-missing radiographic data at each time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change ≤ 0.5 at Year 2 [N=83, 92, 89]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change ≤ 0.5 at Year 10 [N=83, 93, 90]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change ≤ 0 at Year 2 [N=83, 92, 89]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change ≤ 0 at Year 10 [N=83, 93, 90]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Score of ACR50 Plus No Change in Modified Total Sharp Score</title>
        <time_frame>Year 10</time_frame>
        <population>This outcome measure was not analyzed due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.</description>
          </group>
          <group group_id="O3">
            <title>Adalimumab + Methotrexate</title>
            <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Score of ACR50 Plus No Change in Modified Total Sharp Score</title>
          <population>This outcome measure was not analyzed due to a protocol amendment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure</title>
        <description>A major clinical response was defined as maintenance of an ACR70 response for at least a 6-month continuous period at any time during the study following the first dose of adalimumab. A participant was a responder if the following criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient’s self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).</description>
        <time_frame>From the first dose of adalimumab (at Week 1 or Week 106 for patients initially randomized to methotrexate in the DB phase) to Year 10</time_frame>
        <population>ITT Analysis Set for participants with non-missing ACR data.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Adalimumab</title>
            <description>Participants received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase. During the 8-year open-label phase all participants received adalimumab 40 mg every other week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure</title>
          <description>A major clinical response was defined as maintenance of an ACR70 response for at least a 6-month continuous period at any time during the study following the first dose of adalimumab. A participant was a responder if the following criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient’s self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-Reactive Protein).</description>
          <population>ITT Analysis Set for participants with non-missing ACR data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure</title>
        <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A decrease in the HAQ-DI score represents an improvement in physical function; a clinically significant improvement is defined as a decrease of least 0.22 from Baseline in the HAQ-DI score. The number of participants with improvement in HAQ-DI of at least 0.22 and 0.5 units from Baseline is reported.</description>
        <time_frame>Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.</time_frame>
        <population>ITT Analysis Set, with available data. The Number of Participants Analyzed indicates patients with non-missing HAQ-DI scores at any post-baseline time point; &quot;N&quot; indicates patients with non-missing data at each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab: HAQ Decrease ≥ 0.22</title>
            <description>Participants with a decrease of least 0.22 in HAQ from baseline, who received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase and adalimumab 40 mg every other week during the 8-year open-label phase.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab: HAQ Decrease ≥ 0.5</title>
            <description>Participants with a decrease of least 0.5 in HAQ from baseline, who received either methotrexate (MTX), adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase and adalimumab 40 mg every other week during the 8-year open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure</title>
          <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A decrease in the HAQ-DI score represents an improvement in physical function; a clinically significant improvement is defined as a decrease of least 0.22 from Baseline in the HAQ-DI score. The number of participants with improvement in HAQ-DI of at least 0.22 and 0.5 units from Baseline is reported.</description>
          <population>ITT Analysis Set, with available data. The Number of Participants Analyzed indicates patients with non-missing HAQ-DI scores at any post-baseline time point; &quot;N&quot; indicates patients with non-missing data at each specified time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="692"/>
                <count group_id="O2" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 [N=407]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 [N=390]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 [N=344]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10 [N=170]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the double-blind treatment phase, up to 2 years (Methotrexate, Adalimumab and Adalimumab + Methotrexate reporting groups). For the Any Adalimumab reporting group, adverse events include the open-label extension, and are reported for up to 10 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Methotrexate</title>
          <description>Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
        </group>
        <group group_id="E2">
          <title>Adalimumab</title>
          <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase.</description>
        </group>
        <group group_id="E3">
          <title>Adalimumab + Methotrexate</title>
          <description>Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase.</description>
        </group>
        <group group_id="E4">
          <title>Any Adalimumab</title>
          <description>Participants received either methotrexate, adalimumab, or methotrexate + adalimumab during the 2-year double-blind treatment phase. During the 8-year open-label phase all participants received adalimumab 40 mg every other week.
Adverse events reported include those that occurred at any time during adalimumab exposure (up to 10 years).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="320" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Corneal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Corneal opacity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Necrotising scleritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal wall cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Calcinosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Corneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Epstein-barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Meningitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mycobacterium marinum infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neurological infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Post-operative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Testicular injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>CSF pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatitis c antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bone erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bone fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Knee deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>B-cell small lymphocytic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colon cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colon cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lymphoma cutis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Enchondromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hair follicle tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Clonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hyperreflexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intention tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Uterine cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vocal cord cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Foot operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Female sterilization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Aortitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rheumatoid vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="241" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="634" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="131" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="98" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="219" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="176" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="111" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="132" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="109" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="129" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="108" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="189" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="155" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="98" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="153" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

